Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.74 |
| ▸ | ACLY | P53396 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL11050684 | 1.00 | THRB (0.74) | THRBACLYALDH1A1L3MBTL1TET2 | |
| SCHEMBL31083846 | 0.97 | THRB (0.78) | THRBACLYALDH1A1L3MBTL1TET2 | |
| SCHEMBL37922 | 0.97 | THRB (0.78) | THRBACLYALDH1A1L3MBTL1TET2 | |
| SCHEMBL4582407 | 0.94 | THRB (0.74) | THRBACLYALDH1A1L3MBTL1TET2 | |
| SCHEMBL10694667 | 0.94 | THRB (0.74) | THRBACLYALDH1A1L3MBTL1TET2 | |
| SCHEMBL3086542 | 0.94 | THRB (0.74) | THRBACLYALDH1A1L3MBTL1TET2 | |
| SCHEMBL28574326 | 0.94 | THRB (0.74) | THRBACLYALDH1A1L3MBTL1TET2 | |
| Hydrochloric Acid SCHEMBL808878 | 0.94 | THRB (0.74) | THRBACLYALDH1A1L3MBTL1TET2 | |
| Fluoride SCHEMBL648538 | 0.94 | THRB (0.74) | THRBACLYALDH1A1L3MBTL1TET2 | |
| SCHEMBL29571684 | 0.94 | THRB (0.74) | THRBACLYALDH1A1L3MBTL1TET2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8647445-B1 | Process for cleaning semiconductor devices and/or tooling during manufacturing thereof | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2014-02-11 | — | — | US | claimed |
| EP-0939785-B1 | PERFLUOROELASTOMER COMPOSITION HAVING ENHANCED CURING PERFORMANCE | DU PONT (US) | 2003-04-23 | — | — | EP | claimed |
| EP-0939785-A1 | PERFLUOROELASTOMER COMPOSITION HAVING ENHANCED CURING PERFORMANCE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-09-08 | — | — | EP | claimed |
| WO-1998023675-A1 | PERFLUOROELASTOMER COMPOSITION HAVING ENHANCED CURING PERFORMANCE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-06-04 | — | — | WO | claimed |
| US-5677389-A | HIGH TEMPERATURE HEAT RESISTANCE, CHEMICAL RESISTANCE | E. I. DU PONT DE NEMOURS (US) | 1997-10-14 | — | — | US | claimed |
| EP-2610533-B1 | SEAL MEMBER | DAIKIN IND LTD (JP) | 2025-01-15 | — | — | EP | disclosed |
| CN-119029497-A | Separator for secondary battery and secondary battery | 大金工业株式会社 | 2024-11-26 | — | — | CN | disclosed |
| US-11742491-B2 | Binder for secondary battery, electrode mixture for secondary battery, electrode for secondary battery and secondary battery | DAIKIN INDUSTRIES, LTD. (JP) | 2023-08-29 | — | — | US | disclosed |
| EP-4144774-A1 | COMPOSITE, POLYMER ELECTROLYTE, ELECTROCHEMICAL DEVICE, POLYMER-BASED SOLID CELL, AND ACTUATOR | Daikin Industries, Ltd. (JP) | 2023-03-08 | — | — | EP | disclosed |
| US-11394083-B2 | Secondary battery separator including porous film having fluorine-containing polymer of vinylidene fluoride, tetrafluoroethylene, and vinyl carboxylic acid or salt and secondary battery including the same | DAIKIN INDUSTRIES, LTD. (JP) | 2022-07-19 | — | — | US | disclosed |
| CN-113517140-A | Working electrolyte for improving hydration resistance of low-voltage aluminum electrolytic capacitor and preparation method thereof | 西安交通大学 | 2021-10-19 | — | — | CN | disclosed |
| US-20210292450-A1 | COMPOSITION, CROSSLINKED RUBBER MOLDED ARTICLE AND FLUORINE-CONTAINING POLYMER | DAIKIN INDUSTRIES, LTD. (JP) | 2021-09-23 | — | — | US | disclosed |
| CN-101316810-A | Ionic liquids | BIONIQS LTD (GB) | 2008-12-03 | — | — | CN | disclosed |
| US-20080200399-A1 | Compounds for Treating Neurologic Diseases, Otologic Diseases, or Ophthalmologic Diseases and Methods of Use Thereof | PROTOR PHARMA CORP. | 2008-08-21 | — | — | US | disclosed |
| EP-1805207-A1 | TREATMENT OF TRAUMATIC OR DEGENERATIVE NEUROLOGIC, OTOLOGIC, OR OPHTHALMOLOGIC DISEASES WITH TARGETED PROTEASE INHIBITORS | Ceptor Corporation (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006037133-A1 | TREATMENT OF TRAUMATIC OR DEGENERATIVE NEUROLOGIC, OTOLOGIC, OR OPHTHALMOLOGIC DISEASES WITH TARGETED PROTEASE INHIBITORS | CEPTOR CORPORATION (US) | 2006-04-06 | — | — | WO | disclosed |
| EP-0939785-B1 | PERFLUOROELASTOMER COMPOSITION HAVING ENHANCED CURING PERFORMANCE | DU PONT (US) | 2003-04-23 | — | — | EP | disclosed |
| EP-0939785-A1 | PERFLUOROELASTOMER COMPOSITION HAVING ENHANCED CURING PERFORMANCE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-09-08 | — | — | EP | disclosed |
| WO-1998023675-A1 | PERFLUOROELASTOMER COMPOSITION HAVING ENHANCED CURING PERFORMANCE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
| US-5677389-A | HIGH TEMPERATURE HEAT RESISTANCE, CHEMICAL RESISTANCE | E. I. DU PONT DE NEMOURS (US) | 1997-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200399-A1 | Compounds for Treating Neurologic Diseases, Otologic Diseases, or Ophthalmologic Diseases and Methods of Use Thereof | OTC, CLN6, OAT | THRB 3095/4885ACLY 1018/4885ALDH1A1 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.